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Abstract
Purpose Multiple endocrine neoplasia type 1 is a rare tumor syndrome caused by germline mutations ofMEN1 gene. Phenotype
varies widely, and no definitive correlation with the genotype has been observed. Mutation-negative patients with MEN1-
associated tumors represent phenocopies. By comparing mutation-positive and mutation-negative patients, we aimed to identify
phenotype features predictive for a positive genetic test and to evaluate the role of MEN1 mutations in phenotype modulation.
Methods Mutation screeening of MEN1 gene by Sanger sequencing and assessment of clinical data of 189 consecutively
enrolled probands and relatives were performed at our national and European Reference Center. Multiple ligation probe
amplification analysis of MEN1 gene and Sanger sequencing of CDKN1B were carried out in clinically suspicious but
MEN1-negative cases.
Results Twenty-seven probands and twenty family members carried MEN1 mutations. Five mutations have not been
described earlier. Pronouncedly high number of phenocopies (>70%) was observed. Clinical suspicion of MEN1 syndrome
emerged at significantly earlier age in MEN1-positive compared to MEN1-negative probands. Gastroenteropancreatic
neuroendocrine tumors developed significantly earlier and more frequently in carriers compared to non-carriers. Probands
with high-impact (frameshift, nonsense, large deletions) mutations, predicted to affect menin function significantly,
developed GEP-NETs more frequently compared to low-impact (inframe and missense) mutation carriers.
Conclusions MEN1 phenocopy is common and represents a significant confounder for the genetic testing. GEP-NET under
30 years best predicted a MEN1 mutation. The present study thus confirmed a previous proposal and suggested that GEP-
NET under 30 years should be considered as a part of the indication criteria for MEN1 mutational analysis.
Keywords Multiple endocrine neoplasia type 1 ● Neuroendocrine tumors ● Gastroenteropancreatic neuroendocrine tumor ●
Phenocopy ● Genotype–phenotype associations
* Attila Patócs
patocs.attila@med.semmelweis-univ.hu
1 2nd Department of Medicine, Semmelweis University,
Budapest, Hungary
2 “Lendület” Hereditary Endocrine Tumors Research Group,
Hungarian Academy of Sciences – Semmelweis University,
Budapest, Hungary
3 Department of Laboratory Medicine, Semmelweis University,
Budapest, Hungary
4 Kenézy Gyula Hospital, Debrecen, Hungary
5 Markhot Ferenc Hospital, Eger, Hungary
6 2nd Department of Pathology, Semmelweis University,
Budapest, Hungary
7 Division of Endocrinology, Department of Medicine, Faculty of
Medicine, University of Debrecen, Debrecen, Hungary
8 Kaposi Mór County Hospital, Kaposvár, Hungary
9 1st Department of Medicine, University of Szeged,
Szeged, Hungary
10 MTA-SE Molecular Medicine Research Group, Hungarian
Academy of Sciences – Semmelweis University,
Budapest, Hungary
Supplementary information The online version of this article (https://
doi.org/10.1007/s12020-019-01932-x) contains supplementary
material, which is available to authorized users.
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
Introduction
Multiple endocrine neoplasia type 1 (MEN1) is a rare,
autosomal dominantly inherited tumor syndrome caused by
germline mutations of the tumor suppressor MEN1 gene,
with an estimated prevalence of 1–10/100,000 individuals
[1, 2]. Most common manifestations include primary
hyperparathyroidism (PHPT), pituitary adenomas (PA), and
gastroenteropancreatic neuroendocrine tumors (GEP-NET).
The tumors of the affected endocrine organs in
MEN1 syndrome appear earlier than the sporadic ones.
Their penetrance increases with age, although considerable
phenotypic variability has been reported [3, 4].
Of the three major manifestations, PHPT has the highest
penetrance and is considered to appear first in MEN1,
although it often remains unrecognised [5]. Recent pub-
lications show, that functionally active GEP-NETs, initially
frequently diagnosed as sporadic ones, lead to diagnosis of
MEN1 in a remarkable proportion of patients [6]. Compared
to sporadic tumors, MEN1-associated GEP-NETs are
diagnosed 10 years earlier and often in a multiple form
[5, 7], and their penetrance is as high as 80–90%, reaching
nearly that of the parathyroid adenomas [6]. Non-
functioning GEP-NETs are increasingly recognised due to
advanced imaging modalities such as endoscopic ultrasound
and thus became the most common type in MEN1 patients
[8]. Although MEN1-associated GEP-NETs seem to have a
low proliferation rate and long survival has been reported,
they should be of particular attention, since they are still the
principal cause of death in MEN1 patients [9, 10]. There are
only a few studies comparing MEN1-associated versus
sporadic GEP-NETs, and there are no unequivocal pieces of
information about the possible differences regarding their
prognosis [7, 9].
The criteria of diagnosis and the indication for MEN1
mutation analysis have been described in the Endocrine
Society guideline published in 2012 [8]. In 5–10% of
MEN1 patients no mutation of the MEN1 gene can be
found. In these cases simultaneous development of endo-
crine tumors usually associated with MEN1 mutations
results in phenocopy [8]. Mutations of other genes might be
responsible for a MEN1-like phenotype. Rare mutations of
the CDKN1B gene encoding the cyclin dependent kinase
inhibitor p27 causes the MEN1-like MEN4 syndrome [11].
Involvement of the CaSR, AIP, and CDC73 genes was also
demonstrated as a cause of MEN1-like syndromes [12].
Here, we present our experience with genetic diagnosis
of MEN1 syndrome as a Hungarian national reference
center from the last 17 years. MEN1 mutation analysis was
performed in all patients with clinical suspicion of
MEN1 syndrome. MEN1 mutation-positive and mutation-
negative subjects were compared in order to identify pre-
dictive factors for true MEN1 cases.
Subjects and methods
Subjects
MEN1 genetic test is available at our national referral center
since 2001. A total of 189 patients, 134 unrelated probands
and 55 family members of the mutation-positive pedigrees
were examined for germline mutations. Between January
2001 and December 2017, patients were consecutively
enrolled from all over Hungary and all data available were
collected retrospectively. Of the 134 probands, 104 cases
fulfilled the criteria of MEN1 mutational analysis of the
Endocrine Society published in 2012 [8]. All available first-
degree relatives of the index cases genetically diagnosed
with MEN1 were enrolled. Because of the limited avail-
ability of data regarding family history, the familial or
sporadic origin of the disease could not be reliably deter-
mined in all cases. Clinical information was obtained from
the responsible endocrinologists. Diagnosis of the mani-
festations was established according to the corresponding
guidelines [8]. Further regular screening for tumors of the
affected organs was performed in mutation-positive cases
and in mutation-negative patients presenting with clinical
MEN1 syndrome, in line with the widely accepted recom-
mendations [3, 8]. Clinical data were studied together with
laboratory, imaging, and histological results.
Genetic analysis
Detection of disease-causing germline mutations of the
MEN1 gene was carried out using genomic DNA isolated
from peripheral blood samples in all patients. The coding
regions of the MEN1 gene were PCR-amplified and were
subjected to Sanger sequencing as described earlier [13, 14].
The new mutations found in MEN1 gene were considered
pathogenic based on their association with clinical
MEN1 syndrome. Patients carrying a frameshift, nonsense,
splice site mutation or large deletion were considered hav-
ing a high-impact mutation. Those with a missense or
inframe mutations were grouped as low-impact mutation
carriers.
Due to the infrequent occurence of both large deletions in
theMEN1 gene and mutations of the CDKN1B gene, further
genetic analysis was performed in those 15 suspicious,
MEN1 mutation-negative cases, who either developed all
the three major manifestations, or presented two major
manifestations before the age of 40 years. In these pro-
bands, MLPA analysis was performed to detect large
deletions of the MEN1 gene, using SALSA MLPA probe-
mix kit P017-D1 according to the manufacturer’s instruc-
tions (MRC-Holland, Amsterdam, The Netherlands). For
CDKN1B mutation analysis, the two coding exons of
CDKN1B were PCR-amplified and directly Sanger
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sequenced using predesigned primer pairs (exon 1 forward
primer (E1F): 5′ CGC TTT GTT TTG TTC GGT TT 3′;
exon 1 reverse primer (E1R): 5′ ATA CGC CGA AAA
GCA AGC TA 3′; exon 2 forward primer (E2F): 5′ TAA
AAG CCA CTG GGG ATG AC 3′; exon 2 reverse primer
(E2R): 5′ CAG TGC GTG CTC CTT TAG TG 3′). The
PCR and sequecing protocols were described earlier [13–
15].
Statistical analysis
Dell Statistica (data analysis software system), version 13.
(Dell Inc. (2016), software.dell.com.) was used for statistical
analysis. Correlations between mutational status and clinical
manifestations were calculated with χ2 and Fisher’s exact
test. For examining the differences in age, Student’s inde-
pendent samples’ T-test was used. For the examination of
difference between age-related penetrances Kaplan–Meier
curves were plotted and analyzed using log-rank (Mantel-
Cox) test. In all comparisons, p-value < 0.05 was considered
statistically significant.
Results
Results of genetic testing
A total of 189 patients, including 134 unrelated probands
and 55 family members were enrolled in this study. MEN1
mutation was identified in 47 cases: 27 probands and 20
family members. All of the 20 family members shared the
same mutations as their index relatives. Of the 134 pro-
bands, the criteria for MEN1 genetic testing were fulfilled in
104 cases (78 women and 26 men). No mutation was found
in those patients who did not fit in the criteria of mutational
analysis. Supplementary Table 1 contains detailed clinical
and genetic data.
The 104 proband cases with clinical suspicion of MEN1
included 27 (26%) mutation-positive and 77 (74%)
mutation-negative patients. We found 24 different MEN1
gene mutations among these patients. Three patients carried
c.1546_1547insC frameshift mutation in exon 10, two of
them developed pancreatic NET under 30 years of age, the
third patient had both metastatic pancreatic and bronchial
NET. The c.202_206dupGCCCC mutation in exon 2 was
identified in two probands. Ten mutations were described in
our previous studies [13, 16], and further eight mutations
have been reported formerly in the literature. To the best of
our knowledge, of the 24 MEN1 gene mutations, five (c.19
C>T, p.Gln7STOP in exon 2; c.1160delA in exon 8;
c.1399delG in exon 10; c.166_167insA in exon 2 and
c.168delC in exon 2) have not yet been published, thus
these were regarded as novel mutations (chromatograms of
the mutated sequences can be found in Supplementary Fig.
1). We found 15 mutation-negative cases (19.2%) that either
presented all the three major tumors, or developed two
major manifestations before 40 years of age. CDKN1B gene
sequencing and MLPA analysis of the MEN1 gene were
carried out on these samples and in one case the deletion of
exon 6 of MEN1 was detected by MLPA.
Twelve mutation-positive index cases had familial
MEN1 syndrome, while 11 had sporadic disease. In four
cases, the familial or sporadic origin could not be deter-
mined. The family history in all MEN1-negative cases was
negative, thus they are considered clinically sporadic. Thirty
seven of the 77 mutation-negative probands (48.1%) ful-
filled the criteria of clinical MEN1 syndrome, moreover,
three of them developed all the three main manifestations of
the syndrome (their age at the onset of PHPT was 48, 50
and 53 years; of PA 49, 50 and 53 years; of GEP-NET 46,
47 and 53 years, respectively). In accordance, the propor-
tion of phenocopy within the sporadic patients fulfilling the
criteria for clinical MEN1 syndrome (11 MEN1-positive
sporadic patients and 37 MEN1-negative sporadic patients)
was 77.1% (37/48).
Indications of MEN1 mutation analysis
The first clinical manifestation of the mutation-positive
probands was PHPT and GEP-NET, both in 33.3% of
patients, while PA presented in 26.0% as the first tumor. In
one patient, bronchial NET appeared first. In MEN1-nega-
tive patients, PHPT, PA, and GEP-NET was the earliest
tumor in 49.4, 27.3 and 13.0% of cases, respectively. Two
mutation-negative patients developed adrenal adenomas
before the appearance of PHPT, and in 7.8% information
about the first tumor lacked. Figure 1 shows the indications
for MEN1 genetic testing. The most common indications
were PHPT together with PA and PHPT under 30 years
similarly in both MEN1 mutation carriers and non-carriers.
It is remarkable that multiple GEP-NETs presented quite
often at the beginning of the clinical course of the disease,
being a common indication for genetic testing in mutation
carriers.
Of the 55 first-degree relatives, 20 carried MEN1 muta-
tions, and six of them did not have any signs or symptoms
of MEN1. The youngest patient that underwent MEN1
genetic testing was 6 years old, nonetheless, this patient
inherited the mutation.
Incidence and age-related penetrance of MEN1-
associated tumors
The mean follow-up period lasted for 8.5 years. The mor-
tality rate in MEN1 mutation carriers and non-carriers was
14.8 (4/27) and 6.5% (5/77), respectively, which was not
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statistically significant (p= 0.186). However, three of the
four MEN1 patients died because of GEP-NET (at the age
of 35, 44 and 67 years; 10, 19 and 19 years after diagnosis,
respectively), compared to only two of the five MEN1-
negative probands (at the age of 44 and 56; 3 and 3 years
after diagnosis, respectively). The suspicion of
MEN1 syndrome emerged at significantly earlier age in
MEN1 mutation carriers compared to non-carriers (31.4 ±
12.6 vs. 40.2 ± 17.3 years, p= 0.019, Table 1). The inci-
dence of GEP-NET was significantly higher already at
initial presentation in mutation-positive compared to
mutation-negative probands (44.4% vs. 20.8%, p= 0.017,
not shown). Significantly higher prevalence of recurrent
PHPT (55.6% vs. 9.1%, p < 0.001), PA (66.7% vs. 39.0%,
p= 0.013), GEP-NET (70.4% vs. 23.4%, p < 0.001) and
multiple GEP-NET (29.6% vs. 3.9%, p < 0.001) was
observed in mutation-positive compared to mutation-
negative cases (Table 1). Not only a significantly higher
occurence of GEP-NET was associated with the mutant
allele, but these tumors also developed significantly earlier
in carriers (31.0 ± 12.2 vs. 45.9 ± 16.1 years, p= 0.004).
More than the half of GEP-NETs in mutation-positive
probands evolved under 30 years, compared to only 16.7%
of GEP-NETs in non-mutant cases (p < 0.001). The com-
bination of at least two of the three major tumors, as
expected, correlated significantly with the carrier state. Any
two of the three major tumors developed under 30 years of
age represented a high predictive value (positive predictive
value; PPV= 72.2%) for MEN1 mutation. Apart from the
coexistence of the three main manifestations, GEP-NET
under 30 years of age best predicted a positive MEN1
genetic test (PPV= 78.6%).
The age-related penetrance of the development of
MEN1 syndrome suspicion (according to the aforemen-
tioned criteria [8]) was significantly higher in mutation-
positive compared to mutation-negative probands (Fig. 2);
50% penetrance was achieved at the age of 27.7 vs. 41.4
years, respectively. Similarly, significantly higher age-
related penetrance of the development of GEP-NET was
observed in mutation-positive patients, with 50% pene-
trance at the age of 26.8 compared to 46.2 years in
mutation-negative probands.
Histological type of tumors
The most common histological type of MEN1-associated
GEP-NET was insulinoma (47.4%), followed by non-
functioning pancreatic adenoma (31.6%) and gastrinoma
(15.8%), with an overall penetrance of 33.3%, 22.2% and
11.1% among MEN1 patients, respectively. One patient
developed glucagonoma and one patient was diagnosed
with an ACTH-secreting NET. Three mutation-carrier pro-
bands had NETs of other origin: two patients had bronchial,
and one had thymic NET. In contrast, insulinoma was
present in only 22.2% of mutation-negative probands, while
gastrinomas were more frequent (27.8%), whereas non-
functioning tumors (22.2%) had similar frequencies. Three
mutation-negative patients developed ileal carcinoids
(16.7%), one patient had glucagonoma and one had
VIPoma. None of the mutation-negative patients had either
thymic or bronchial NET.
The majority of PAs in both mutation-positive and
-negative probands was functional. The most common
type of PA in MEN1-positive probands was prolactinoma
(66.7%). Growth hormone (GH)—PRL-producing, GH-
producing and follicle-stimulating hormone (FSH)—
luteinizing hormone (LH)-producing adenomas were rare
(11.1%, 5.6%, 5.6% of PAs, respectively). 11.1% of PAs
were non-functioning. 33.3% of PAs of mutation-negative
patients were GH-producing adenomas. Prolactinomas
and non-functioning PAs were less frequent (both had
16.7% prevalence) and 6.7% of PAs produced adreno-
cotricotropic hormone (ACTH). In 26.7% of MEN1-
negative cases, the data about hormonal activity was not
available.
Fig. 1 Indications for MEN1 mutational analysis. The diagram shows
manifestations that led to mutational analysis in mutation-positive
(n= 27, marked with black) and mutation-negative (n= 77, marked
with gray) probands. The criteria for analysis were defined according
to the Endocrine Society guideline published in 2012 [8]. The group
“multiple GEP-NET” includes both patients with multiple GEP-NETs
of the same histological type and patients with multiple GEP-NETs of
different subtypes. MEN1 multiple endocrine neoplasia type 1, PHPT
primary hyperparathyroidism, PA pituitary adenoma, GEP-NET gas-
troenteropancreatic neuroendocrine tumor
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Genotype–phenotype correlations
Following the concept of distinction between high- and
low-impact mutations described above, we separated the
mutation-positive probands into two groups to evaluate the
possible influence of the mutation type on clinical outcome
(Table 2). High-impact mutations included 12 frameshift
mutations (44.4%, six deletions and six insertions), seven
nonsense mutations (25.9%), one intronic splice-site muta-
tion, and one large deletion. Low-impact mutations
encompassed five missense mutations (18.5%) and one
inframe deletion. GEP-NET had a significantly higher fre-
quency among patients carrying high-impact mutations
compared to those with low-impact mutations (81.0% vs.
33.3%, p= 0.044).
The most frequent location of mutations in the MEN1
gene was exon 2 (40.7%), followed by exon 10 (18.5%). No
mutations were detected in exons 5 and 7. No significant
association was found between the affected exons and the
clinical features.
Discussion
Our study aimed to collect and analyze the clinical and
genetic data of all Hungarian patients who underwent MEN1
genetic testing at our national referral center. The estimated
frequency of germline MEN1 mutations in the Hungarian
population according to our present data is 0.48/100,000
individuals, which is somewhat lower than expected [1].
However, compared to the recently published multicenter
study of the Italian MEN1 database comprising 410 patients
[17], the prevalence of MEN1 mutations and the relative
number of affected pedigrees in the whole population are
similar to our findings. The mutation detection rate (the
percentage of the mutation-positive cases among the index
patients) in our study was 26%, similarly to the Swedish
MEN1 cohort [18]. Additionally, of the 24 different MEN1
mutations, five have not been documented yet.
Apart from the 27 genetically confirmed MEN1 index
cases, 77 unrelated index patients with signs and symptoms
Table 1 Comparison of clinical
characteristics of MEN1
mutation-positive and mutation-
negative probands
Mutation-positive
probands (n= 27)
Mutation-negative
probands (n= 77)
p-value % of mutation-
positive
probands (PPV)
Age at MEN1 syndrome
suspicion* (years)
31.4 ± 12.6 40.2 ± 17.3 0.019 NA
PHPT 27 (100.0%) 69 (89.6%) 0.082 27/96 (28.1%)
Recurrent PHPT* 15 (55.6%) 7 (9.1%) <0.001 15/22 (68.2%)
Age at PHPT (years) 33.4 ± 13.7 40.3 ± 17.9 0.082 NA
PHPT under 30 years 13 (48.2%) 26 (33.8%) 0.184 13/39 (33.3%)
PA* 18 (66.7%) 30 (39.0%) 0.013 18/48 (37.5%)
Age at PA (years) 29.8 ± 14.2 39.5 ± 16.5 0.053 NA
GEP-NET* 19 (70.4%) 18 (23.4%) <0.001 19/37 (51.4%)
Multiple GEP-NET* 8 (29.6%) 3 (3.9%) <0.001 8/11 (72.7%)
Age at GEP-NET* 31.0 ± 12.2 45.9 ± 16.1 0.004 NA
GEP-NET under 30 years*
(years)
11 (40.7%) 3 (3.9%) <0.001 11/14 (78.6%)
2 major manifestations under
30 years*
13 (48.1%) 5 (6.5%) <0.001 13/18 (72.2%)
PHPT+ PA* 18 (66.7%) 26 (33.8%) 0.003 18/44 (40.9%)
PHPT+GEP-NET* 19 (70.4%) 12 (15.6%) <0.001 19/31 (61.3%)
PA+GEP-NET* 12 (44.4%) 5 (6.5%) <0.001 12/17 (70.6%)
PHPT+ PA+GEP-NET* 12 (44.4%) 3 (3.9%) <0.001 12/15 (80.0%)
The table presents the frequency of the manifestations regarding genotype (i.e., mutation-positive or
-negative), with the related p-values, in those probands who fulfilled the criteria of the mutation analysis
(n= 104). The last column shows the positive predictive value (PPV) of each manifestation, that is: the
proportion of mutation-positive probands among all patients carrying the manifestation. The manifestations
signed with * mean significant associations. The group “multiple GEP-NET” includes both patients with
multiple GEP-NETs of the same histological type as well as patients with multiple GEP-NETs of different
subtypes
The bold values are significant
MEN1 multiple endocrine neoplasia type 1, PHPT primary hyperparathyroidism, PA pituitary adenoma,
GEP-NET gastroenteropancreatic neuroendocrine tumor, PPV positive predictive value, NA not applicable
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resembling MEN1 syndrome were referred to our labora-
tory. Neither of these cases had MEN1 mutation. Hence, the
percentage of sporadic MEN1 patients with phenocopy was
77.1% (37/48 cases), higher than previously estimated.
Information about the proportion of MEN1 syndrome
phenocopy is scarce, especially when distinguishing
familial cases from sporadic ones. In these latter cases
MEN1 mutations occur far less frequently, in 33–65% of
cases as previously reported [19]. As lately stated, such
sporadic co-occurence of the main MEN1-associated
endocrine tumors is presumably much more common than
thought [20].
The most common indication for MEN1 testing is the
combination of PHPT and PA. They also occur frequently
in the general population, thus their coexistence cannot be
negligible. However, to the best of our knowledge, the exact
frequency of the combination of these sporadic tumors is
not known. Based on previous studies [20, 21], the co-
occurence may be roughly estimated as high as 0.8–5.3/
10,000 individuals, however, still considered a rare disease
according to the Orphanet criterion [22].
Considering the low frequency of MEN1 mutations and
the high proportion of phenocopy in this population, one
specific aim of the present study was to determine key
factors which predispose to a positive result of the mutation
screening by analyzing the differences between mutation-
positive and mutation-negative patients. These findings may
be useful for the clinician to identify those patients that most
likely carry a MEN1 mutation.
Since mutation-positive probands met the criteria for
MEN1 mutation screening at significantly earlier age than
mutation-negative probands, we confirmed the previously
described findings that younger age is a predisposing factor
for a positive result during MEN1 mutation analysis [2].
Moreover, the presence of any two of the three major
tumors in patients under 30 years was highly predictive for
a MEN1 mutation. A considerable proportion of both
MEN1-positive and MEN1-negative patients presented with
PHPT either under 30 years or together with PA. This
finding reflects the high prevalence and coincidence of these
sporadic tumors in the general population, leading to phe-
nocopy [8]; and also raises the issue of whether PHPT under
30 years implies a clear indication for MEN1 mutational
analysis.
The presence of GEP-NET implied the strongest pre-
disposing factor regarding MEN1 mutational positivity,
already at initial presentation. Moreover, MEN1-associated
GEP-NETs developed more than 15 years earlier than
sporadic ones. Nonetheless, GEP-NET was the first clinical
manifestation in one third of MEN1 probands. Conse-
quently, of all the manifestations, the presence of GEP-NET
under 30 years best predicted an underlying germlineMEN1
mutation. In accordance, Jensen et al. [23] found that
MEN1-associated pancreaticoduodenal endocrine tumors
(PDETs) are usually diagnosed one decade earlier than their
sporadic counterparts. Furthermore, PDETs have been
reported to be frequently the manifestation that leads to
MEN1 diagnosis [5]. In line with previous studies, ENETS
Fig. 2 Age-related penetrance of
the developement of
MEN1 syndrome presumption
(a) and the major
manifestations: PHPT (b), PA
(c), and GEP-NET (d) in MEN1-
positive vs. MEN1-negative
probands with the same
manifestation. P-values marked
with * mean significant
associations. MEN1 multiple
endocrine neoplasia type 1,
PHPT primary
hyperparathyroidism, PA
pituitary adenoma, GEP-NET
gastroenteropancreatic
neuroendocrine tumor
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consensus guidelines already recommended MEN1 genetic
testing in patients with insulinoma before 20 years [24]. De
Laat et al. [20] suggested lately, that mutational analysis
should be extended to all patients with pancreatic NETs
before 20 years of age. The present study, although with a
limited number of cases, first evidenced this proposal: GEP-
NET before 30 years should be especially considered to be
included in the criteria of MEN1 mutational analysis. This
finding should certainly be confirmed on larger cohorts.
Five hundred and seventy-six different germline muta-
tions of the MEN1 gene were annotated between 1997 and
2015 [25, 26]. Concolino et al. [26] found a portion of
66.5% of frameshift, nonsense or splice site mutations,
while Pardi et al. [27] and Lemos et al. [25] reported almost
the same proportion as in our cohort (73% vs. 74%). There
have been several attempts to find genotype–phenotype
correlations regarding MEN1 syndrome. The functional
effects of MEN1 mutations have been widely investigated.
One theory states that truncating (frameshift, nonsense)
mutations may result in a consequent loss of functional
domains, while the non-truncating (missense) forms cause
inactivation of functionally critical amino acid residues
[25]. Consequently, some studies report about the correla-
tion between frameshift mutations and pancreatic neu-
roendocrine tumors [1, 28]. Instead, Machens reported no
correlation between the type of mutation and the clinical
features [29]. Accordingly with the recommendations of the
American College of Medical Genetics and Genomics
(ACMG) [30] and upon our results, MEN1 genetic variants
might also be categorized as low- and high-impact variants,
which confer some limited prognostic differences. In our
study, 11 out of 12 MEN1 patients with frameshift mutation
had GEP-NET. High-impact MEN1 mutation carriers were
more likely to develop GEP-NETs than patients with low-
impact mutations, resulting in a geno-phenotype correlation,
which is of importance regarding the genetic counseling and
the prognosis of MEN1 syndrome.
Our study presents some limitations, mainly as a con-
sequence of the limited sample size. The clinical informa-
tion may be incomplete in some cases, and the variable
follow-up period did not allow us to draw firm conclusions
regarding long-term disease course. The lack of symptoms
and the limited availability of sensitive radiological meth-
ods presumably contributed to the underestimated propor-
tion of non-functioning GEP-NETs in our cohort. Because
of the limited possibility to test patients for large MEN1
deletions with MLPA and for CDKN1B mutations, some of
these mutations could have been missed.
In conclusion, we performed a comprehensive genetic
and clinical analysis of the Hungarian MEN1 cohort. As a
national and European Reference Center we have built the
Hungarian MEN1 database, which may be of great interest
in further work coordinated by the European Reference
Network on Rare Endocrine Conditions (Endo-ERN,
https://endo-ern.eu/). Based on our results a multicentric,
international study has been initialised within the Endo-
ERN in order to clarify whether our findings could be
confirmed in large cohorts and consequently may lead to the
modification of the criteria for MEN1 mutation testing. The
beneficial effect of routine screening of presymptomatic
individuals has been recently debated [31] and even the
timing of genetic testing of presymptomatic indviduals is
questioned. The psychological distress and lower health-
related quality of life in MEN1-positive individuals also
indicate that this topic is highly relevant in everyday clinical
practice [32]. We revealed a considerable proportion of
patients with a high suspicion of MEN1 syndrome but
without pathogenic MEN1 mutation, resulting in pheno-
copy. Thus we aimed to find clinical features that most
likely predict an underlying MEN1 mutation by comparing
mutation-positive and -negative patients. GEP-NET
Table 2 Frequency of the manifestations in probands with high- and
low-impact mutations, with the related p-values
High-impact
mutation
carriers
(n= 21)
Low-impact
mutation
carriers (n= 6)
p-value
Age at MEN1 syndrome
suspicion (years)
30.6 ± 11.6 34.5 ± 17.6 0.543
PHPT 21 (100.0%) 6 (100.0%) 1.000
Recurrent PHPT 12 (57.1%) 3 (50.0%) 0.557
Age at PHPT (years) 33.1 ± 13.3 34.4 ± 16.9 0.856
PHPT under 30 years 11 (52.4%) 2 (33.3%) 0.362
PA 14 (66.7%) 4 (66.7%) 0.677
Age at PA (years) 27.9 ± 14.2 39.0 ± 12.0 0.230
GEP-NET* 17 (81.0%) 2 (33.3%) 0.044
Multiple GEP-NET 7 (33.3%) 1 (16.7%) 0.430
Age at GEP-NET
(years)
31.5 ± 11.9 26.6 ± 12.5 0.602
GEP-NET under
30 years
10 (47.6%) 1 (16.7%) 0.189
2 major manifestations
under 30 years
12 (57.1%) 1 (16.7%) 0.080
PHPT+ PA 14 (66.7%) 4 (66.7%) 0.677
PHPT+GEP-NET* 17 (81.0%) 2 (33.3%) 0.044
PA+GEP-NET 10 (47.6%) 2 (33.3%) 0.443
PHPT+ PA+GEP-
NET
10 (47.6%) 2 (33.3%) 0.443
The manifestation signed with * mean significant associations. The
group “multiple GEP-NET” includes both patients with multiple GEP-
NETs of the same histological type and patients with multiple GEP-
NETs of different subtypes
The bold values are significant
MEN1 multiple endocrine neoplasia type 1, PHPT primary hyperpar-
athyroidism, PA pituitary adenoma, GEP-NET gastroenteropancreatic
neuroendocrine tumor
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appeared significantly earlier and more frequently inMEN1-
positive probands, and its development under 30 years best
predicted a positive genetic test. Hereby we confirmed a
lately raised suggestion and thus recommend extending the
MEN1 mutational analysis to all patients presenting GEP-
NETs before 30 years. Moreover, MEN1 patients with high-
impact MEN1 mutations were more likely to develop GEP-
NETs revealing an interesting geno-phenotypic association
in MEN1 syndrome with potential prognostic consequences
regarding genetic counseling. Finally we must add, as it has
been previously confirmed many times, that despite the
large number of negative results, genetic analysis is inevi-
table in suspicious cases of the dominantly inherited, highly
penetrant MEN1 syndrome [2, 4, 33].
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